Strategy
Stages
Early clinical-stage (Phase 1/2)
Sectors
Biotech
Check size
$15M-$30MRecent changes
- Sep 6, 2026Sep 6, 2026Sectors updated: Biotech ascentacap.com
- Sep 6, 2026Sep 6, 2026Check size updated: $15M-$30M ascentacap.com
- Sep 6, 2026Sep 6, 2026Stages updated: Early clinical-stage (Phase 1/2) ascentacap.com
Portfolio
2 totalCo-Investors
125AM Ventures · 1 sharedBlue Owl Capital · 1 sharedForesite Capital · 1 sharedQatar Investment Authority · 1 sharedSanofi Ventures · 1 sharedWestlake Village BioPartners · 1 sharedAtlas Venture · 1 sharedCormorant Asset Management · 1 sharedDeep Track Capital · 1 sharedFidelity Investments · 1 sharedJanus Henderson Investors · 1 sharedOrbiMed Advisors · 1 shared
Latest Pulse
- Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in ImmunologyTriveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.→
- Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology TherapeuticsTriveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.→